BR112016011605A2 - Composição de um inibidor de transcriptase reversa não nucleosídeo - Google Patents

Composição de um inibidor de transcriptase reversa não nucleosídeo

Info

Publication number
BR112016011605A2
BR112016011605A2 BR112016011605A BR112016011605A BR112016011605A2 BR 112016011605 A2 BR112016011605 A2 BR 112016011605A2 BR 112016011605 A BR112016011605 A BR 112016011605A BR 112016011605 A BR112016011605 A BR 112016011605A BR 112016011605 A2 BR112016011605 A2 BR 112016011605A2
Authority
BR
Brazil
Prior art keywords
composition
reverse transcriptase
inhibitor
nucleoside reverse
transcriptase inhibitor
Prior art date
Application number
BR112016011605A
Other languages
English (en)
Other versions
BR112016011605A8 (pt
Inventor
Lowinger Michael
S Tatavarti Aditya
Jules Marsac Patrick
J M Ploeger Kristin
J Bloom Corey
Anne BROOKHART Katherine
M Baumann John
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112016011605A2 publication Critical patent/BR112016011605A2/pt
Publication of BR112016011605A8 publication Critical patent/BR112016011605A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO DE UM INIBIDOR DE TRANSCRIPTASE REVERSA NÃO NUCLEOSÍDEO. A invenção abrange uma composição compreendendo o inibidor de transcriptase reversa (RT) 3-cloro-5-({1-[(4-metil-5-oxo-4,5-di-hidro-1H-1,2,4- triazol-3-il)metil]-2-oxo-4-(trifluorometil)-1,2-di-hidropiridin-3- il}óxi)benzonitrila suficientemente misturado em um polímero de intensificação de concentração, e processos de preparação do mesmo. A composição e os processos da presente invenção melhoram significativamente a biodisponibilidade do inibidor de RT acima mencionado, mantendo a estabilidade física.
BR112016011605A 2013-11-22 2014-11-19 Composição de um inibidor de transcriptase reversa não nucleosídeo BR112016011605A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907537P 2013-11-22 2013-11-22
PCT/US2014/066281 WO2015077273A1 (en) 2013-11-22 2014-11-19 Composition of a non-nucleoside reverse transcriptase inhibitor

Publications (2)

Publication Number Publication Date
BR112016011605A2 true BR112016011605A2 (pt) 2017-08-08
BR112016011605A8 BR112016011605A8 (pt) 2023-04-25

Family

ID=53180083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011605A BR112016011605A8 (pt) 2013-11-22 2014-11-19 Composição de um inibidor de transcriptase reversa não nucleosídeo

Country Status (11)

Country Link
US (1) US20160287568A1 (pt)
EP (1) EP3071037A4 (pt)
JP (2) JP6387094B2 (pt)
KR (2) KR20220158860A (pt)
CN (1) CN105722392B (pt)
AU (1) AU2014353177B2 (pt)
BR (1) BR112016011605A8 (pt)
CA (1) CA2929499C (pt)
MX (1) MX2016006645A (pt)
RU (2) RU2016124545A (pt)
WO (1) WO2015077273A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3383397T (lt) 2015-12-02 2021-11-25 Merck Sharp & Dohme Corp. Farmacinės kompozicijos, kurių sudėtyje yra doravirinas, tenofoviro dizoproksilo fumaratas ir lamivudinas
RU2729792C1 (ru) * 2019-07-29 2020-08-12 Акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" Способы повышения растворимости лекарственного средства на основе пиримидинового производного бензофенона

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2008540629A (ja) * 2005-05-19 2008-11-20 ファイザー・インク 非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物
JP5243247B2 (ja) * 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品
RU2008119412A (ru) * 2005-10-19 2009-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) N-фенил-фенилацетамидные ненуклеозидные ингибиторы обратной транскриптазы
JP5773560B2 (ja) * 2006-02-09 2015-09-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｅｔｐ阻害剤のポリマー製剤
CA2646335A1 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2009069014A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Amorphous lamivudine and its preparation
US9724664B2 (en) * 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
RU2435584C2 (ru) * 2009-10-28 2011-12-10 Закрытое Акционерное Общество "Фармфирма "Сотекс" Пролонгированная фармацевтическая композиция, лекарственная форма и способ ее изготовления (варианты)
ME02181B (me) * 2010-03-30 2015-10-20 Merck Canada Inc Ne-nukleozidni inhibitori reverzne transkriptaze
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体

Also Published As

Publication number Publication date
EP3071037A1 (en) 2016-09-28
AU2014353177A1 (en) 2016-05-05
MX2016006645A (es) 2016-12-16
RU2016124545A (ru) 2017-12-27
JP2018193396A (ja) 2018-12-06
CN105722392B (zh) 2019-07-23
CN105722392A (zh) 2016-06-29
JP6387094B2 (ja) 2018-09-05
KR20220158860A (ko) 2022-12-01
CA2929499C (en) 2019-01-08
JP2016537332A (ja) 2016-12-01
KR102601617B1 (ko) 2023-11-10
WO2015077273A1 (en) 2015-05-28
BR112016011605A8 (pt) 2023-04-25
AU2014353177B2 (en) 2018-03-15
KR20160079816A (ko) 2016-07-06
RU2661399C1 (ru) 2018-07-16
CA2929499A1 (en) 2015-05-28
US20160287568A1 (en) 2016-10-06
EP3071037A4 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CY1123295T1 (el) Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης
CL2015000942A1 (es) Compuestos de benceno sustituido.
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
CL2015001655A1 (es) Compuestos derivados de ftalazin-1(2h)-ona, inhibidores selectivos de la poli(adp-ribosa) polimerasa-1; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201691619A1 (ru) Конденсированные гетероциклические соединения
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
EA201791304A1 (ru) Производные изохинолина для лечения вич
UA117251C2 (uk) 4-членні кільцеві карбоксамідні сполуки, що застосовуються як нематоциди
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2016009332A (es) Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CL2015002897A1 (es) Inhibidores de bace1
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
MX2017014235A (es) Formulaciones de emulsion estable de compuestos volatiles encapsulados.
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
BR112016011605A2 (pt) Composição de um inibidor de transcriptase reversa não nucleosídeo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/40

Ipc: A61K 31/4439 (2006.01), A61P 31/14 (2006.01), A61P

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)